Claus Rehfeld

TrialSync is a B2B software company (SaaS) specializing in patient recruitment and retention for clinical trials. Our platform streamlines the recruitment process for sponsors, CROs, and clinical trial sites by leveraging automated pre-screening, AI-driven patient matching, and real-time recruitment dashboards. We specialize in general research and rare diseases. TrialSync ensures trial timelines are met by connecting sponsors with eligible participants while reducing administrative burden. Our tools promote efficiency and transparency, helping sponsors manage multiple campaigns, track performance metrics, and optimize resource allocation. We are committed to enhancing the patient experience through peer-to-peer recruitment initiatives, community engagement features, and a user-friendly design. TrialSync empowers clinical trials to increase enrollment success rates, improve retention, and accelerate the delivery of life-changing treatments - all while focusing on ethical, sustainable, and patient-centric technology.

Silvi is an end-to-end screening and data extraction tool supporting Systematic Literature Review and Meta-analysis. Silvi helps create systematic literature reviews and meta-analyses that follow Cochrane guidelines in a highly reduced time frame, giving a fast and easy overview. It supports the user through the full process, from literature search to data analyses. Silvi is directly connected with databases such as PubMed and ClinicalTrials.gov and is always updated with the latest published research. It also supports RIS files, making it possible to upload a search string from your favorite search engine (i.e., Ovid). Silvi has a tagging system that can be tailored to any project. Silvi is transparent, meaning it documents and stores the choices (and the reasons behind them) the user makes. Whether publishing the results from the project in a journal, sending them to an authority, or collaborating on the project with several colleagues, transparency is optimal to create robust evidence. Silvi is developed with the user experience in mind. The design is intuitive and easily available to new users. There is no need to become a super-user. However, if any questions should arise anyway, we have a series of super short, instructional videos to get back on track.

The DrugStars ecosystem comprises the scientifically validated DrugStars medication app, the DrugsDisclosed.com our SaaS platform for patients, pharmaceutical companies and payers alike. DrugsDisclosed.com is a free service for patients, patient associations and authorities to access over three million medication experiences from real-world patients. DrugsDisclosed.com collates data from 430,000 patient reviews from global users of the DrugStars medication app, launched by Claus Møldrup in 2017. The service has over 55 million unique data points around medication reviews. It provides anonymous secondary market patient insights for specific medications and conditions. DrugStars is committed to empowering patients. The company donates 20% of its revenues to over 240 global patient organizations and enables the users to earn donations for their chosen organization. To date, DrugStars has donated £376,835 to patient organisations around the world.

We strive to set new global standards for effective and accessible health care communication. Based on scientific research, we combine cutting-edge technology with a profound knowledge of audio-visual communication to create award-winning patient-centric solutions and consultancy for hospitals and healthcare providers. Parallel to our core activities, we work closely with NGOs and health charities to better global health. In this arena, we have developed and scaled the Safe Delivery App – a mobile tool for educating healthcare professionals in the field of Obstetric Emergency Care.

The best way to predict the future is to co-create it. KRING® is a family of impact funds. We co-create new sustainable ventures together with bold entrepreneurs and leading corporate players who are dedicated to building a positive future. Over the years we have co-created and launched more than 20 companies. Some are alive. Some we have killed. Some are acquired. Today our efforts are fully focused on the sustainable development goals. We have our own investment fund that supports our Speedbooting innovation process and enables us to execute fast and focused with co-founders and strategic partners. Through the building of many new ventures and digital companies, we have adopted and adjusted methodologies of entrepreneurship, innovation and co-creation to systematically build new impact ventures together with co-founders and corporates - and help them succeed, grow and create impact. We are committed to using all our efforts on venture building with a strong focus on the SDG agenda, initially Health & Wellbeing (SDG 3) and on Energy (SDG 7). If you are a potential co-founder with a passion for Energy or Health & Wellbeing – let’s talk.

TrialSync is a B2B software company (SaaS) specializing in patient recruitment and retention for clinical trials. Our platform streamlines the recruitment process for sponsors, CROs, and clinical trial sites by leveraging automated pre-screening, AI-driven patient matching, and real-time recruitment dashboards. We specialize in general research and rare diseases. TrialSync ensures trial timelines are met by connecting sponsors with eligible participants while reducing administrative burden. Our tools promote efficiency and transparency, helping sponsors manage multiple campaigns, track performance metrics, and optimize resource allocation. We are committed to enhancing the patient experience through peer-to-peer recruitment initiatives, community engagement features, and a user-friendly design. TrialSync empowers clinical trials to increase enrollment success rates, improve retention, and accelerate the delivery of life-changing treatments - all while focusing on ethical, sustainable, and patient-centric technology.

Silvi is an end-to-end screening and data extraction tool supporting Systematic Literature Review and Meta-analysis. Silvi helps create systematic literature reviews and meta-analyses that follow Cochrane guidelines in a highly reduced time frame, giving a fast and easy overview. It supports the user through the full process, from literature search to data analyses. Silvi is directly connected with databases such as PubMed and ClinicalTrials.gov and is always updated with the latest published research. It also supports RIS files, making it possible to upload a search string from your favorite search engine (i.e., Ovid). Silvi has a tagging system that can be tailored to any project. Silvi is transparent, meaning it documents and stores the choices (and the reasons behind them) the user makes. Whether publishing the results from the project in a journal, sending them to an authority, or collaborating on the project with several colleagues, transparency is optimal to create robust evidence. Silvi is developed with the user experience in mind. The design is intuitive and easily available to new users. There is no need to become a super-user. However, if any questions should arise anyway, we have a series of super short, instructional videos to get back on track.

At DataFair, we have created a unique health data platform. Through collaborations with experts in healthcare, we offer state of the art epidemiological and health economic analyses based on our unique access to and combination of health data. Our aim is to gather insight from both existing and new data sources. This includes sources such as traditional registry data from Denmark’s more than 160 data registries, sensory data, and personally generated behavioral data. Research using our platform has already begun. As of 2022, DataFair is involved in three health analytical projects: HedaX, OSCAR and CLIC.

At DataFair, we have created a unique health data platform. Through collaborations with experts in healthcare, we offer state of the art epidemiological and health economic analyses based on our unique access to and combination of health data. Our aim is to gather insight from both existing and new data sources. This includes sources such as traditional registry data from Denmark’s more than 160 data registries, sensory data, and personally generated behavioral data. Research using our platform has already begun. As of 2022, DataFair is involved in three health analytical projects: HedaX, OSCAR and CLIC.

The DrugStars ecosystem comprises the scientifically validated DrugStars medication app, the DrugsDisclosed.com our SaaS platform for patients, pharmaceutical companies and payers alike. DrugsDisclosed.com is a free service for patients, patient associations and authorities to access over three million medication experiences from real-world patients. DrugsDisclosed.com collates data from 430,000 patient reviews from global users of the DrugStars medication app, launched by Claus Møldrup in 2017. The service has over 55 million unique data points around medication reviews. It provides anonymous secondary market patient insights for specific medications and conditions. DrugStars is committed to empowering patients. The company donates 20% of its revenues to over 240 global patient organizations and enables the users to earn donations for their chosen organization. To date, DrugStars has donated £376,835 to patient organisations around the world.